论文部分内容阅读
为明确黄芪甲苷(AST)在生物样品中的稳定性和在大鼠体外肠菌代谢转化产物及代谢途径。本实验采用体外的方法对AST在人工胃液、人工肠液及大鼠肝匀浆中的稳定性以及大鼠离体肠道菌群中的代谢产物进行探讨。采用HPLC法测定AST在生物样本中的含量,计算AST在生物样本中的剩余百分率。采用TLC,HPLC和LC-MS/MS相结合的分析手段,鉴定代谢产物。结果发现,AST在人工胃液、人工肠液及肝脏中均较稳定,不易代谢;AST肠道菌群的代谢是通过脱糖基逐级进行的。首先,失去3位木糖基转化成次生代谢产物环黄芪醇-6-O-β-D-吡喃葡萄糖苷(CMG)。然后,失去6位葡萄糖基得到极性更小的皂苷元环黄芪醇(CAG)。研究结果表明AST在体内主要在肠道代谢,发生糖基水解作用。即肠道菌群的水解作用是AST代谢的主要原因。
To clarify the stability of astragaloside (AST) in biological samples and the metabolic products and metabolic pathways of enterobacteria in vitro in rats. In this study, the stability of AST in artificial gastric juice, artificial intestinal juice and rat liver homogenate as well as the metabolites of rat intestinal flora were studied in vitro. The content of AST in the biological sample was determined by HPLC, and the remaining percentage of AST in the biological sample was calculated. By TLC, HPLC and LC-MS / MS analysis of the combination of means to identify metabolites. The results showed that, AST in artificial gastric juice, artificial intestinal juice and liver are more stable and difficult to metabolize; AST intestinal flora metabolism through the deglycosylation step by step. First, the conversion of 3-xylosyl to the secondary metabolite of cyclophosphamide-6-O-β-D-glucopyranoside (CMG) was lost. Then, the 6-glucosyl group was lost to give the sapogenin, cyclosporin (CAG), which is less polar. The results show that AST in the body mainly in the intestinal metabolism, the occurrence of glycosylation. Intestinal flora of the hydrolysis is the main cause of AST metabolism.